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Iron is an essential metal for all living organisms. However, iron homeostasis needs to be tightly controlled since iron can mediate
the production of reactive oxygen species, which can damage cell components and compromise the integrity and/or cause DNA
mutations, ultimately leading to cancer. In eukaryotes, iron-regulatory protein 1 (IRP1) plays a central role in the control of
intracellular iron homeostasis. This occurs by interaction of IRP1 with iron-responsive element regions at 5' of ferritin mRNA and
3' of transferrin mRNA which, respectively, represses translation and increases mRNA stability. We have expressed IRP1 using
the plasmid pT7-His-hIRP1, which codifies for human IRP1 attached to an NH2-terminal 6-His tag. IRP1 was expressed in
Escherichia coli using the strategy of co-expressing chaperonins GroES and GroEL, in order to circumvent inclusion body
formation and increase the yield of soluble protein. The protein co-expressed with these chaperonins was obtained mostly in the
soluble form, which greatly increased the efficiency of protein purification. Metal affinity and FPLC ion exchange chromatography
were used in order to obtain highly purified IRP1. Purified protein was biologically active, as assessed by electrophoretic mobility
shift assay, and could be converted to the cytoplasmic aconitase form. These results corroborate previous studies, which
suggest the use of folding catalysts as a powerful strategy to increase protein solubility when expressing heterologous proteins
in E. coli.
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Introduction
Iron is an essential metal present as a prosthetic group in
proteins such as hemoglobin, myoglobin, and cytochromes.
However, it is also a potential source of reactive oxygen
species (ROS) (1). Thus, iron levels need to be tightly
controlled in order to keep a pool of “free” iron low enough
not to cause cell damage. Iron is brought from the blood
stream to the cells by transferrin, which binds to the transfer-
rin receptor and is internalized into the cell. Inside the cells,
vesicles containing iron-loaded transferrin/transferrin recep-
tor are acidified, releasing iron, which is then used as a
component of the prosthetic group for several proteins (2).
Unused iron is stored by ferritin (3), preventing this metal
from catalyzing ROS generation. The control of iron entry
into the cell depends on the number of transferrin receptors,
which are regulated by iron-regulatory protein (IRP) (4). IRP
also regulates the synthesis of ferritin (5). When iron levels
are low, transferrin receptor mRNA stability is increased by
binding of IRP to iron-regulatory element (IRE) sequences at
3'-UTR. On the other hand, ferritin synthesis is inhibited by
binding of IRP to IRE sequences at 5'-UTR of its mRNA,
preventing protein translation (6-8). Two IRPs have been
described: IRP1, which is more abundant and shows a
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mutually exclusive aconitase activity (6,9), and IRP2, which
lacks this enzymatic activity (10). Binding of IRP1 to IRE
sequences occurs when protein is devoid of a 4Fe-4S
cluster as opposed to a situation in which the cluster and
aconitase activity are present (11).
IRP1 is also activated in response to other stimuli. ROS
(12-14) as well as reactive nitrogen species (15,16) have
been shown to activate IRP1. It has also been shown that
IRP1 can be phosphorylated and activated by protein
kinase C (17), which makes iron-regulatory mechanisms
even more complex.
Heterologous protein expression often needs to be ad-
dressed in many different ways in order to be successful.
Escherichia coli is commonly used to produce recombinant
proteins from several sources. Once protein is cloned and
the expression vector is transferred to bacteria, expression
conditions need to be optimized. These include shaker speed,
temperature and absorbance (600 nm) used for expression
induction (18,19). After all these efforts, the protein of interest
may be produced in an insoluble form as inclusion bodies.
Soluble protein recovery from these inclusion bodies is a
difficult and often unsuccessful task. The use of molecular
chaperonins to facilitate soluble protein expression has been
adopted in some systems with success (20-24). Chaperonins
are ubiquitous proteins that have an important role in the
folding of newly synthesized proteins in vivo. The bacterial
GroEL/GroES chaperonin complex is composed of two
heptameric rings of GroEL and an attached heptameric lid of
GroES, which assemble forming a “double doughnut” struc-
ture. Unfolded protein enters into this chamber and is folded
in an ATP-dependent mechanism (25,26). It is estimated that
10-15% of all cytoplasmic proteins depend on GroEL/GroES
under normal growth conditions in order to fold correctly (27).
Under heat stress, this number increases to 30%.
We have expressed IRP1 in E. coli using a plasmid
containing the human IRP1 sequence attached to an NH2-
terminal 6-His tail. Expression of soluble IRP1 was only
poor using this system. On the other hand, co-expression
of IRP1 with chaperonins GroEL/GroES greatly improved
the expression levels of soluble IRP1. This facilitated IRP1
purification, performed in two sequential steps: first with an
Ni2+-Sepharose column and then by FPLC ion exchange
chromatography. Protein purity was higher than 99%. IRP1
activity was confirmed by its ability to bind an IRE se-
quence in an electrophoretic mobility shift assay (EMSA).
Material and Methods
Material
Bromophenol blue, dithiothreitol, EDTA, HEPES, NP-
40, heparin, ß-mercaptoethanol (EtSH), and Trizma were
purchased from Sigma (USA). Acrylamide and bisacryl-
amide were from Bio-Rad (Hercules, USA). N,N,N’,N’-
tetramethylethylenodiamine was from Fluka (Buchs SG,
Switzerland). α-[32P]-UTP was from GE Healthcare (USA).
All other reagents were of analytical grade.
Plasmids
The plasmid pSPT-fer (4), kindly provided by Dr. Lukas
Kühn (Lausanne, Switzerland), contains the IRE sequence
for ferritin and the T7 and SP6 promoters. Plasmid pT7-
His-hIRP1 was kindly provided by Dr. Mathias W. Hentze
(Heidelberg, Germany). pT7-His-hIRP1 contains the se-
quence for human IRP1 fused to a 6-His tag, a T7 RNA
polymerase promoter and an ampicillin selection marker.
IRP1 expression
IRP1 was expressed in BL21(DE3) E. coli strains trans-
formed with plasmid pT7-His-hIRP1, previously transformed
with plasmid pT-GroE, that codes for chaperonins GroEL
and GroES. E. coli strains containing pT-GroE (20) were
kindly provided by Dr. Shunsuke Ishii (University of Tsuku-
ba, Japan). Colonies selected for both plasmids were
inoculated into 5 mL Luria-Bertani medium containing 200
µg/mL carbenicillin and 20 µg/mL chloramphenicol and
grown overnight at 37°C. This 5-mL culture was then
inoculated into 500 mL Luria-Bertani medium containing
200 µg/mL carbenicillin and 20 µg/mL chloramphenicol
and grown at 25°C, 150 rpm, until absorbance (600 nm)
0.9-1.0. Shaker speed was reduced to 80 rpm and protein
expression was induced by the addition of 1 mM IPTG for
3 h. After this time, cells were centrifuged at 14,000 g, 4°C,
for 10 min, and stored at -20°C until purification.
IRP1 purification
The bacterial pellet was defrosted, resuspended in
lysis buffer (250 mM NaCl, 0.5% NP-40, 20 mM Tris-HCl,
pH 8.0) and sonicated. Lysed bacteria were centrifuged at
14,000 g, 4°C, for 10 min. Purification was carried out in
two steps. First, the supernatant was loaded onto a 2-mL
Chelating Sepharose Fast Flow column (GE Healthcare),
previously charged with Ni2+ ions, according to a modifica-
tion of the protocol described by Gray et al. (28). Protein
was loaded onto the column after adjusting the KCl con-
centration in the supernatant to 400 mM in order to inhibit
non-specific binding. The column was washed with 8 mL
washing buffer (WB, 24 mM HEPES, pH 7.6, 150 mM
potassium acetate, 1.5 mM MgCl2, 5% glycerol) containing
400 mM KCl and then with 8 mL WB. Two other sequential
washing steps were performed with 8 mL WB containing
10 and 20 mM imidazole. Elution was carried out with 10
mL WB containing 50 mM imidazole, with 2-mL fractions
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being collected. The column was further washed sequen-
tially with WB containing 100 and 200 mM imidazole. The
purity of the fractions was analyzed by SDS-PAGE and
Coomassie blue staining and fractions containing higher
amounts of IRP1 were pooled and loaded onto a MonoQ
HR 5/5 ion exchange column coupled to an FPLC appara-
tus (GE Healthcare). Protein was eluted using a KCl gradi-
ent with a 4%/min slope and a flow rate of 1 mL/min. The
purity of the fractions was analyzed by SDS-PAGE, Coo-
massie blue staining and densitometry. Quantification of
the bands was done with the ImageQuant TL Software (GE
Healthcare). Protein measurements were carried out with
the Bradford assay (29).
Measurement of IRP1 activity by electrophoretic
mobility shift assay
RNA probe and binding to IRP1. The 32P-labeled probe
was synthesized using RiboProbe Gemini II from Promega
(USA), plasmid pSPT-fer as a template and α-[32P]-UTP.
The binding reaction was carried out as described (5). The
following reagents were added to a 1.5-mL test tube: 2 µg
purified IRP1 diluted in 4 µL Munro buffer (MB, 10 mM
HEPES, pH 7.6, 3 mM MgCl2, 40 mM KCl, 5% glycerol, 1
mM DTT), 4 µL MB, with or without 4% EtSH (2% final
concentration), 0.1 ng of the [32P]-RNA probe (15,000 cpm)
in 4 µL MB, one unit RNase T1 in 4 µL MB (to degrade
unprotected RNA, not bound to IRP1), 4 µL MB containing
50 mg/mL heparin and 4 µL of sample buffer (30 mM Tris-
HCl, pH 7.5, 40% sucrose, 0.2% bromophenol blue). Each
addition was followed by a brief spin to mix the reagents.
EtSH, at the concentration used in the assay, fully activates
IRP1 in vitro by reducing 4Fe-4S cluster sulfhydryl groups
(30), which allows standardizing IRP1 activation as a func-
tion of the total amount of protein that can be activated.
Electrophoretic mobility shift assay. The method fol-
lowed was essentially the one described by Konarska and
Sharp (31). Samples were submitted to 6% acrylamide gel
electrophoresis at 200 V. At the end of the run, the gel was
dried in a Bio-Rad gel drier (USA), exposed for 24-48 h to
a PhosphorImager Screen and read on a Storm Phosphor-
Imager System (Molecular Dynamics, USA). Bands on the
gel represent shifted bands of IRP1 bound to a 32P-labeled
IRE-containing RNA probe. Results were analyzed with
the ImageQuant Software (Molecular Dynamics).
Reassembly of 4Fe-4S cluster in vitro and conversion of
IRP1 to cytosolic aconitase
The IRP1 4Fe-4S cluster was reassembled by the meth-
od of Gray et al. (28). Briefly, approximately 20 ng IRP1 was
incubated with 10 mM cysteine and 50 µM FeSO4 for 30 min
at 22°C. Conversion of IRP1 to cytosolic aconitase was
indicated by the loss of IRP1 activity assayed by EMSA.
Results and Discussion
IRP1 plays a central role in iron homeostasis in eukary-
otes, controlling the levels of the iron storage protein
ferritin and the iron uptake protein transferrin receptor.
This process is carried out by its binding to IRE sequences
present in ferritin and transferring receptor mRNAs. In
order to study the properties of recombinant IRP1, Gray et
al. (28) and Brazzolotto et al. (32) expressed the protein in
E. coli, recovering soluble IRP1. We made several at-
tempts to express IRP1 in E. coli transformed with the
same plasmid pT7-His-hIRP1, changing temperature,
shaker speed and absorbance (600 nm) used for protein
induction. However, we were not successful in these at-
tempts, since most of the protein was produced in an
insoluble form and we were unable to recover it by solubi-
lization and renaturation. In an attempt to solve this prob-
lem, we decided to use folding catalysts to help expression
of the protein in a soluble form, an approach that has been
used by other investigators with success (20-24). The
simultaneous expression of the bacterial chaperonins
GroES/GroEL using the pT-GroE plasmid highly increased
the expression of soluble IRP1, as shown in Figure 1.
Figure 1. Increase in the solubility of IRP1 by co-expression of
chaperones GroES and GroEL. IRP1 was expressed in the
BL21(DE3) Escherichia coli strain in the presence (+GroESL) or
absence (-GroESL) of GroES and GroEL. IRP1 expression was
induced or not with IPTG for 3 h and protein patterns for the
soluble (s) and insoluble fractions (p) were analyzed by SDS-
PAGE with Coomassie blue staining. IRP1 = iron-regulatory
protein 1; i = samples induced with 1 mM IPTG; M = molecular
weight marker.
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Figure 2. Kinetics of IRP1 induction by IPTG for the bacterial
clone that co-expresses IRP1 and GroEL. IRP1 was co-ex-
pressed in BL21(DE3) Escherichia coli strains expressing GroES
and GroEL. IRP1 expression was induced with IPTG from 20 to
180 min, and protein patterns for the soluble (s) and insoluble
fractions (p) were analyzed by SDS-PAGE with Coomassie blue
staining. IRP1 = iron-regulatory protein 1; i = samples induced
with 1 mM IPTG; M = molecular weight marker.
Figure 3. IRP1 purification using an Ni2+-NTA column. IRP1 was
co-expressed in BL21(DE3) Escherichia coli strains expressing
GroES and GroEL. IRP1 expression was induced with IPTG for 3
h, and soluble protein fractions were analyzed by SDS-PAGE
with Coomassie blue staining. ft = flow-through; lanes 1,2 = wash
with and without 400 mM KCl, respectively; lanes 3,4 = wash with
10 and 20 mM imidazole; lanes 5-9 = fractions eluted with 50 mM
imidazole; lanes 10-14 = fractions eluted with 100 mM imidazole;
lane 15 = fraction eluted with 150 mM imidazole. IRP1 = iron-
regulatory protein 1. M = molecular weight marker.
Figure 4. IRP1 purification using ion exchange chromatography.
Protein fractions 6-8, from Figure 3, were loaded onto a MonoQ
column coupled to an FPLC apparatus. Elution was carried out
with a KCl gradient until 1 M. The figure shows SDS-PAGE
protein profiles stained with Coomassie blue. M = molecular
weight marker; lane 1 = injected sample; lane 2 = fraction eluted
before the salt gradient; lanes 3,4 = fractions eluted in 200 mM
KCl; lanes 5-11 = fractions eluted between 200 and 300 mM KCl,
containing purified IRP1; lane 12 = pooled fractions eluted be-
tween 300 and 600 mM KCl; lane 13 = pooled fractions eluted
between 600 and 900 mM KCl. IRP1 = iron-regulatory protein 1.
Optimal protein expression was achieved 90 min after
induction with IPTG (Figure 2) and only a small amount of
protein was present in the insoluble fraction.
IRP1 was then purified by metal affinity chromatogra-
phy using an Ni2+-NTA column. Protein was loaded with a
KCl concentration of 400 mM in order to minimize non-
specific binding to the column. The column was washed
with WB containing the same KCl concentration and then
without KCl. The column was washed with WB containing
10-20 mM imidazole and protein was eluted with the same
buffer containing 50 mM imidazole. In order to ensure that
most of the protein was eluted with 50 mM imidazole,
concentrations of 100 and 150 mM were also used to wash
the column thereafter. Figure 3 shows that most IRP1 was
eluted in the fractions containing 50 mM imidazole. The
increase in IRP1 expression highly improved the efficiency
of protein purification, since fractions that were much more
enriched in IRP1 were obtained. Before the co-expression
strategy, IRP1 was estimated to represent less than 10%
of the total protein eluted with 50 mM imidazole. After the
co-expression with chaperonins, IRP1 represented about
87% of the total protein eluted under the same conditions.
Following the first purification step, we used a second
step of FPLC ion exchange chromatography to eliminate
the contaminating bands shown in Figure 3, lanes 6-8. For
this purpose, the fractions represented in these lanes,
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which were eluted with 50 mM and contained most IRP1,
were loaded onto a MonoQ column. Elution was performed
with a KCl gradient. As shown in Figure 4, IRP1 was eluted
in fractions containing 200-300 mM KCl in high purity,
estimated to be above 99% by gel densitometry.
In order to test if IRP1 remained biologically active,
purified protein was tested for its ability to bind an IRE-
containing ferritin mRNA fragment. For this purpose, frac-
tions obtained after ion exchange chromatography were
assayed by EMSA. In this assay, total IRP1-binding activ-
ity is achieved by in vitro treatment with a potent reducing
agent, ß-mercaptoethanol (EtSH) (30), which allows stan-
dardizing IRP1 activation as a function of the total amount
of protein that can be activated. Figure 5A shows that
fractions 5 through 11 from Figure 4, which correspond,
respectively, to lanes 1-7 in Figure 5, present high IRE-
binding activity, above 90% in most bands, compared to
totally activated protein. In order to check if IRP1 could be
converted to the cytosolic aconitase form, we treated puri-
fied IRP1 with 10 mM cysteine and 50 µM FeSO4, a
protocol know to convert one form to the other, as de-
scribed by Gray et al. (28). EMSA results are shown in
Figure 5B. IRP1 treatment with FeSO4 and cysteine re-
sulted in the abolition of IRP1 activity, probably due to the
reassembly of the 4Fe-4S cluster and consequent conver-
sion to cytosolic aconitase. Thus, apparently, neither co-
expression of IRP1 with chaperonins nor the presence of
the 6His-tag on the protein affected its ability to be con-
verted to cytosolic aconitase.
The use of molecular chaperonins to solubilize ex-
pressed proteins has been described by others. Yasukawa
et al. (20) described the effect of co-expressing chaperonins
GroES and GroEL, as well as the redox active protein
thioredoxin, along with vertebrate proteins in E. coli. All the
eight proteins tested showed increased solubility when co-
expressed with thioredoxin. On the other hand, co-expres-
sion of GroES and GroEL increased solubility of four of the
proteins tested. Amrein et al. (21) described the effect of
co-expressing GroES and GroEL in improving solubility of
p50csk protein-tyrosine kinase. Mitsuda and Iwasaki (24)
observed a great improvement in the expression of mem-
brane-bound cytochrome P450 2B6 when co-expressed
with GroES and GroEL in E. coli.
We observed a great improvement in the expression of
soluble IRP1 co-expressed with chaperonins GroES and
GroEL, which substantially facilitated the protein purifica-
tion process. Our results, as well as results from other
investigators, argue for the strategy of co-expressing
chaperonins with the protein of interest in order to solve
problems of protein solubility and expression yield when
Figure 5. Purified IRP1 is biologically active. A, IRP1 activity of fractions eluted from the FPLC was assessed by electrophoretic
mobility shift assay. Two micrograms of each purified IRP1 fraction was incubated with 0.1 ng [32P]-IRE RNA probe (15,000 cpm) and
subjected to non-denaturing electrophoresis on 6% acrylamide gel. The gel was dried and analyzed with the “PhorphorImager”
software. Lanes 1-7 correspond, respectively, to fractions 5-11 from Figure 4. Numbers below the lanes represent the percentage of
IRP1 activity for bands without EtSH, compared to those with EtSH (100% activation). B, IRP1 activity is inhibited by the addition of
FeSO4 and cysteine. Twenty nanograms purified IRP1 was treated with 50 µM FeSO4 and 10 mM cysteine for 30 min at 22°C, and
IRE-binding activity was assayed by electrophoretic mobility shift assay. IRP1 = iron-regulatory protein 1; IRE = iron-responsive
element; EtSH = ß-mercaptoethanol.
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expressing heterologous proteins in E. coli. The crystal
structure of IRP1 in the aconitase form (33) as well as the
crystal structure of IRP1 complexed with ferritin IRE-RNA
(34) were recently solved. However, the high purity of
soluble active IRP1 obtained in this study may facilitate
additional structural studies on IRP1.
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